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process was defined as the state function of some system
whose state at a future time can be probabilistically pre-
dicted from its present state, in a way that cannot be im-
proved by taking account of previous states—known as
the Markov property. Nowadays, many economic mod-
els use the Markov technique and are limited by its prop-
erty. The correctness of this approach is questionable, as
will be addressed in the workshop. In an attempt to ad-
here to a well-known technique, many researchers tend
to ignore the memory component inherent to the disease.
Although this major simplification makes the develop-
ment and computation of these models easier, it often de-
parts substantially from reality. Others circumvent the
consequences of the core philosophy behind the tech-
nique and simulate memory by creating tunnel states.
This only provides a partial, suboptimal solution, how-
ever. We feel researchers should urgently shift their focus
to other modeling approaches better suited to the specific
research question. Although more complicated, the devel-
opment of memory-based models is clearly feasible with
today’s computer capabilities, as we will illustrate based
on our own experience.
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WORKSHOP OBJECTIVE: A modeling approach to the
use of data from a multinational clinical trial for eco-
nomic evaluation of a new product in a specific partici-
pating country is described. Treatment effectiveness is es-
timated based on efficacy data using all participating
countries. Costs to a relevant healthcare perspective and
to society are modeled based on clinical response to treat-
ment combined with health resource use in the specific
country of interest. Costs for patients dropping off study
treatment may be estimated from other sources and used
in the model for a more comprehensive estimate of total
costs and consequences.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved with the design or conduct of economic eval-
uations related to prospective clinical trials.
In many countries, economic evaluation of new products
is required or has come to be expected by regulatory and
clinical audiences rapidly after product launch. Multina-
tional clinical trials powered to estimate efficacy and
safety against a standard treatment using data from all
countries combined have become common in phase III of
the drug development process. Many researchers are us-
ing this valuable opportunity to collect high quality RCT
data on health resource use, quality of life and patient
preferences. In contrast to efficacy and safety informa-
tion, it may not be possible to directly combine health re-
source use from several countries due to between-country
differences in healthcare systems, treatment practice pat-
terns, and healthcare seeking behavior. We describe the
use of a decision tree model to structure the evaluation
with estimates of treatment efficacy, safety, and resource
use collected from the clinical trial.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to develop skills in the analysis of cost data
at the patient level when incomplete follow-up or drop-
outs result in censored cost data. We will identify the
conditions when univariate summary data are unbiased
as well as the conditions when various multivariate tech-
niques using regression analysis and survival analysis are
required for unbiased estimates.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers and analysts involved in the methodological and ana-
lytic aspects of pharmacoeconomic studies as well as
those who want to increase their understanding of the lit-
erature of economic evaluation in clinical trials.
As treatment costs are increasingly determined from indi-
vidual level cost data, analysts have become increasingly
aware of the difficulty in characterizing medical costs for
all individuals for comparable durations of time. It is
common for data on resource use and/or costs not to
cover the entire duration of the study. This may be due to
the final design (e.g., rolling admission and a fixed stop-
ping date), limited commitment to the collection of eco-
nomic data, or individuals dropping out of the economic
study or the administrative database. Different models
for analyzing costs should be used depending on the an-
swers to the following questions: Are the dropouts con-
centrated among the most severe patients? Are the rea-
sons for dropouts related to the treatment drug? Could
the dropouts be related to some unmeasured phenome-
non that is correlated with costs? Is death a possibility
among the dropouts? Practical guidance will be provided
for applying the appropriate methods by critically re-
viewing the statistical models for addressing these issues
using a resent AIDS trial as an example.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to develop a deeper understanding of vari-
